DOCSLIB.ORG

Hormonal Control of Rat Adrenal Phenylethanolamine N-Methyltransferase Enzyme Activity, the Final Critical Pathway Dona L

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hormonal Control of Rat Adrenal Phenylethanolamine N-Methyltransferase Enzyme Activity, the Final Critical Pathway Dona L Hormonal Control of Rat Adrenal Phenylethanolamine N-Methyltransferase Enzyme Activity, the Final Critical Pathway Dona L. Wong, Ph.D., Brenda Siddall, BSc., and Wei Wang, M.S. To examine whether glucocorticoids control rat adrenal but returned corticosterone to hypophysectomized levels phenylethanolamine N-methyltransferase (PN MT) and decreased PNMT mRNA to 50% of normal. Despite through gene transcription, the effects of hypophysectomy the decline in PNMT mRNA and its partial utilization and acute and chronic glucocorticoid replacement on for protein synthesis, PNMT enzymatic activity was fully PNMT mRNA and enzymatic activity were detennined. restored. These findings indicate that glucocorticoids Glucocorticoid depletion through hypophysectomy did not exert marked but complex influences on PNMT gene alter PNMT mRNA, whereas PNMT activity declined to transcription. In addition, corticosteroids appear to rv25% of normal. A single dose of ACTH (4 JU SC) posttranscriptionally regulate PNMT protein expression, rapidly induced PNMT mRNA, with a six-fold peak at 6 underscoring the uncoupling between the expression of hours postinjection. The short-term rise in PNMT PNMT mRNA and active enzyme. Thus, glucocorticoid mRNA was accompanied by an increase in corticosterone control of gene transcription and protein synthesis do not and elevated levels of glucocorticoid receptor mRNA. fully account for changes in PNMT expression, Ribosomal loading experiments suggested that available consistent with the previous observation that PNMT mRNA was fully utilized for protein synthesis. glucocorticoid control of PNMT proteolysis is also However, PNMT activity did not increase commensurately. important in PNMT regulation and the potential for Chronic ACTH treatment (4 JU SC daily for 7 days) epinephrine biosynthesis. [Neuropsychopharmacology sustained elevated levels of glucocorticoid receptor mRNA 13:223-234, 1995] KEY WORDS: Phenylethanolamine N-methyltransferase; nephrine, is a critical determinant of epinephrine ex­ Rat adrenal gland; Honnonal control; Gene expression; pression during acute and chronic stress. In response Enzyme activity to stress, large quantities of glucocorticoids and epi­ The catecholamine biosynthetic enzyme phenylethanol­ nephrine are released from the adrenal gland. Further, amine N-methyltransferase (PNMT, E.C. 2.1.1.28), the glucocorticoids have been demonstrated to affect the final enzyme in the pathway converting tyrosine to epi- expression of PNMT, and it has been suggested that the primary source of this control occurs through PNMT gene expression (Evinger et al. 1992). However, the hormones regulate PNMT still From the Nancy Pritzker Laboratory of Developmental and Mo­ mechanism(s) by which lecular Neurobiology, Department of Psychiatry and Behavioral remains a subject of much controversy. Sciences, Stanford University School of Medicine, Stanford, Cali- Early studies in the adult rat showed that depletion fornia. ' of glucocorticoids through hypophysectomy markedly Address correspondence to: Dona L. Wong, Ph.D., Nancy Pritz­ ker Laboratory of Developmental and Molecular Neurobiology, MSLS reduced PNMT enzymatic activity to ~20% of normal Bldg., Rm P-106, Department of Psychiatry and Behavioral Sciences, values (Ciaranello et al. 1975; Wong et al. 1985; Evinger Stanford University School of Medicine, Stanford, CA 94305-5485. et al. 1992). Basal levels of the enzyme could be restored Received November 29, 1994; revised March 15, 1995; accepted March 28, 1995. by adrenocorticotropin (ACTH) or glucocorticoid ad- NEUROPSYCHOPHARMACOLOGY 1995-VOL. 13, NO. 3 © 1995 American College of Neuropsychopharmacology Published by Elsevier Science Inc. 0893-133X/95/$9 .50 6"'5 Avenue· of the Americas, New York, l\Y 10010 SSDI 0893-133X(95)00066-M 224 D.L. Wong et al. NEUROPSYCHOPHARMACOLOGY 1995-VOL. 13, NO. 3 ministration. However, PNMT enzymatic activity could gene and endogenous PNMT gene expression, al­ never be elevated beyond normal through corticoste­ though dexamethasone, by itself, does not appear to roid manipulation (Ciaranello et al. 1975). Protein turn­ activate either the PNMT-reporter gene construct or the over studies indicated that hormones exerted their endogenous PNMT gene. Deletion mutation and site effects by controlling the rate of protein degradation directed mutagenesis studies demonstrated that Egr-1 without affecting protein synthesis (Ciaranello et al. activation is mediated through two Egr-1 consensus se­ 1975). In the presence of corticosteroids, levels of the quences, a perfect match sequence and an 8/9 match cosubstrate S-adenosylmethionine (SAM), the methyl sequence ( -165 bp and - 45 bp upstream of the site donor for the enzymatic reaction catalyzed by PNMT, of transcription initiation), whereas the glucocorticoid were sustained, and the binding of SAM to PNMT pro­ response is mediated through the GRE (-513 bp) in tected the enzyme against proteolytic degradation the 5' upstream PNMT promoter/regulatory region. (Ciaranello 1978; Berenbeim et al. 1979; Wong et al. It is also evident from in vivo studies that PNMT 1982; Wong et al. 1985). transcriptional activity is likely uncoupled from PNMT More recently it has been demonstrated that PNMT translational activity. For example, when intact rats gene expression is also hormonally regulated. Whereas were administered the type II specific glucocorticoid the effects of hypophysectomy on PNMT mRNA have agonist, RU28362, or the mixed type I and type II glu­ been variable, no change (Wong et al. unpublished; cocorticoid agonist, dexamethasone, PNMT enzymatic Evinger et al. 1992) or marked depletion (Jiang et al. activity declined, falling to 70% of normal levels at a 1989), corticosteroids have consistently been shown to dose of 30 µg daily of dexamethasone or 100 µg daily restore (Jiang et al. 1989) and/or elevate PNMT mRNA of RU28362 (Wong et al. 1992). Whereas higher doses beyond normal levels (Wong et al. 1992; Evinger et al. of RU28362 sustained the attenuation of PNMT, higher 1992) in the adult rat. doses of dexamethasone restored PNMT activity to nor­ Glucocorticoid control of PNMT transcription is mal. PNMT mRNA showed a markedly different pat­ consistent with the presence of a glucocorticoid response tern. Whereas low doses of RU28362 (100 µg daily) did element (GRE) in the 5' upstream promoter/regulatory not change PNMT mRNA levels, high doses (~100 µg sequences of the PNMT gene (Baetge et al. 1988; Kaneda daily) elevated mRNA levels as much as eleven-fold et al. 1988; Batter et al. 1988; Ross et al. 1990; Morita (1,000 µg daily). A similar pattern was observed with et al. 1992). Furthermore, the rat GRE appears func­ dexamethasone except that the rise in PNMT mRNA tional based on the induction of chloramphenicol occurred at a lower dose (30 µg daily) and the incre­ acetyltransferase (CAT) reporter gene activity from a ment in mRNA expression was much greater ( rv2Q fold PNMT-CAT reporter gene construct transiently ex­ at 1,000 µg daily). pressed in bovine chromaf:fm cells (Ross et al. 1990). The present studies were undertaken to further ex­ However, the induction of reporter gene expression by amine the apparent independent effects of glucocorti­ dexamethasone occurred only in cells expressing the coids on PNMT gene and protein expression using a endogenous PNMT gene and required very high corti­ paradigm of glucocorticoid depletion and restoration costeroid concentrations (20 µM). and to determine the relative importance of these mech­ This observation, coupled with evidence demon­ anisms in controlling the critical biologic endpoint, strating that corticosteroids are unable to initiate PNMT PNMT enzymatic activity. Our findings confirm the un­ expression prematurely in the developing rat adrenal coupling of glucocorticoid control of PNMT mRNA and gland or cultured pheochromoblasts (Bohn et al. 1981; protein expression. In response to glucocorticoid deple­ Michelson and Anderson 1992), suggested that gluco­ tion through hypophysectomy, PNMT mRNA expres­ corticoids might be incapable of independently activat­ sion was not significantly reduced, whereas PNMT en­ ing the PNMT gene. Rather, a transcriptional factor, zymatic activity markedly declined. Acute corticosteroid other than the glucocorticoid receptor (GR), might be replacement rapidly elevated PNMT mRNA well be­ necessary to initiate PNMT gene expression, a factor yond normal levels without a concommitant elevation with which the activated GR could then interact to facili­ in PNMT enzymatic activity. In contrast, chronic glu­ tate PNMT gene transcription. cocorticoid replacement therapy restored PNMT enzy­ Consistent with this hypothesis, we have shown matic activity to normal levels although PNMT mRNA recently using transient cotransfection assays that the was reduced to half of normal values. Although PNMT immediate early gene transcriptional protein, Egr-1 mRNA appeared fully and comparably utilized for pro­ (Sukhatme et al. 1988), activates both a PNMT pro­ tein translation in the case of acute corticosteroid moter-luciferase reporter gene construct and the endog­ replacement, it did not appear to be fully utilized in the enous PNMT gene in a PC12 derivative cell line, RSl case of chronic replacement therapy. Clearly, PNMT (Ebert et al. 1994). Further, dexamethasone (1 µM) in­ gene transcription alone is not the limiting event in duces an additional two-fold increment in both reporter PNMT enzymatic expression. NEUROPSYCHOPHARMACOLOGY 1995-VOL. 13, NO. 3 Hormonal Control of
Load more

Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression
    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
    [Show full text]
  • Neurotransmitters-Drugs Andbrain Function.Pdf
    Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Neurotransmitters, Drugs and Brain Function Edited by R. A. Webster Department of Pharmacology, University College London, UK JOHN WILEY & SONS, LTD Chichester Á New York Á Weinheim Á Brisbane Á Singapore Á Toronto Neurotransmitters, Drugs and Brain Function. Edited by Roy Webster Copyright & 2001 John Wiley & Sons Ltd ISBN: Hardback 0-471-97819-1 Paperback 0-471-98586-4 Electronic 0-470-84657-7 Copyright # 2001 by John Wiley & Sons Ltd. Bans Lane, Chichester, West Sussex PO19 1UD, UK National 01243 779777 International ++44) 1243 779777 e-mail +for orders and customer service enquiries): [email protected] Visit our Home Page on: http://www.wiley.co.uk or http://www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P0LP,UK, without the permission in writing of the publisher. Other Wiley Editorial Oces John Wiley & Sons, Inc., 605 Third Avenue, New York, NY 10158-0012, USA WILEY-VCH Verlag GmbH, Pappelallee 3, D-69469 Weinheim, Germany John Wiley & Sons Australia, Ltd.
    [Show full text]
  • 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers
    Japan. J. Pharmacol. 55, 359-366 (1991) 359 2-Phenylethylamine and Methamphetamine Enhance the Spinal Monosynaptic Reflex by Releasing Noradrenaline from the Terminals of Descending Fibers Hideki Ono, Hiroyuki Ito and Hideomi Fukuda' Departmentof Toxicologyand Pharmacology,Faculty of Pharmaceutical Sciences, TheUniversity of Tokyo,Hongo 7-3-1, Bunkyo-ku, Tokyo 113, Japan 'Departmentof Pharmacology, Collegeof Pharmacy,Nihon University, 7-7-1Narashinodai, Funabashi, Chiba 274, Japan ReceivedJuly 28, 1990 AcceptedDecember 27, 1990 ABSTRACT Experiments were performed on spinalized rats transected at C1. In travenous administration of 2-phenylethylamine-HC1 (PEA-HC1) (0.3 and 1 mg/kg, i.v.) and methamphetamine-HC1 (MAP-HC1) (0.1 and 0.3 mg/kg, i.v.) increased the amplitude of the monosynaptic reflex (MSR). The increase of the MSR caused by PEA and MAP was antagonized by prazosin-HC1 and abolished by the pretreatment with reserpine (i.p.) and 6-hydroxydopamine (intracisternally, 14 days previously). A dopamine D, antagonist, SK&F 83566-HBr (0.01 mg/kg, i.v. ), and a D2 antagonist, YM-09151-2 (0.3 mg/kg, i.v.), did not antagonize the increasing effects produced by PEA and MAP. An inhibitor of type-B monoamine oxidase, (-)deprenyl-HC1 (1 mg/kg, i.v.), prolonged the effect of PEA but not that of MAP, suggesting that PEA alone, and not its metabolites, enhanced the MSR. These results suggest that PEA and MAP increase the amplitude of the MSR by releasing noradrenaline from the ter minals of descending noradrenergic fibers, and that PEA, an endogenous trace amine, has a mechanism of action similar to that of MAP.
    [Show full text]
  • Tyramine and Amyloid Beta 42: a Toxic Synergy
    biomedicines Article Tyramine and Amyloid Beta 42: A Toxic Synergy Sudip Dhakal and Ian Macreadie * School of Science, RMIT University, Bundoora, VIC 3083, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-3-9925-6627 Received: 5 May 2020; Accepted: 27 May 2020; Published: 30 May 2020 Abstract: Implicated in various diseases including Parkinson’s disease, Huntington’s disease, migraines, schizophrenia and increased blood pressure, tyramine plays a crucial role as a neurotransmitter in the synaptic cleft by reducing serotonergic and dopaminergic signaling through a trace amine-associated receptor (TAAR1). There appear to be no studies investigating a connection of tyramine to Alzheimer’s disease. This study aimed to examine whether tyramine could be involved in AD pathology by using Saccharomyces cerevisiae expressing Aβ42. S. cerevisiae cells producing native Aβ42 were treated with different concentrations of tyramine, and the production of reactive oxygen species (ROS) was evaluated using flow cytometric cell analysis. There was dose-dependent ROS generation in wild-type yeast cells with tyramine. In yeast producing Aβ42, ROS levels generated were significantly higher than in controls, suggesting a synergistic toxicity of Aβ42 and tyramine. The addition of exogenous reduced glutathione (GSH) was found to rescue the cells with increased ROS, indicating depletion of intracellular GSH due to tyramine and Aβ42. Additionally, tyramine inhibited the respiratory growth of yeast cells producing GFP-Aβ42, while there was no growth inhibition when cells were producing GFP. Tyramine was also demonstrated to cause increased mitochondrial DNA damage, resulting in the formation of petite mutants that lack respiratory function.
    [Show full text]
  • Selegiline) in Monkeys*
    Intravenous self-administration studies with /-deprenyl (selegiline) in monkeys* /-Deprenyl and its stereoisomer d-deprenyl did not maintain intravenous self-administration behavior in rhesus monkeys. In contrast, /-methamphetamine, the major metabolite of /-deprenyl, as well as the baseline drug, cocaine, maintained high rates of intravenous self-administration behavior. Treatment with /-deprenyl doses up to 1.0 mg/kg before self-administration sessions failed to alter self-administra- tion of either cocaine or /-methamphetamine. Thus /-deprenyl did not appear to have cocaine- or meth- amphetamine-like reinforcing properties in monkeys and was ineffective in altering established patterns of psychomotor-stimulant self-administration behavior. These results support clinical findings that de- spite long-term use of /-deprenyl for the treatment of Parkinson's disease by large numbers of patients, no instances of abuse have been documented. /-Deprenyl has recently been suggested as a potential med- ication for the treatment of various types of drug abuse, including cocaine abuse, but its failure to pro- duce selective effects in decreasing cocaine or methamphetamine self-administration behavior in the present experiments makes such an application seem unlikely. (CLIN PHARMACOL THER 1994;56:774-80.) Gail D. Winger, PhD,a Sevil Yasar, MD,b'd'e S. Steven Negus, PhD,a and Steven R. Goldberg, pIli/i d'e Ann Arbor, Mich., and Baltimore, Md. From the 'Department of Pharmacology, University of Michigan /-Deprenyl (selegiline) has been known for several
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information C om pany 300 North Z eeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800 521-0600 Order Number 9120692 Part 1. Synthesis of fiuorinated catecholamine derivatives as potential adrenergic stimulants and thromboxane A 2 antagonists. Part 2.
    [Show full text]
  • The Enigma of Conditioned Taste Aversion Learning: Stimulus Properties of 2-Phenylethylamine Derivatives
    Physiol. Res. 51: S13-S19, 2002 The Enigma of Conditioned Taste Aversion Learning: Stimulus Properties of 2-phenylethylamine Derivatives A. J. GREENSHAW1, S. TURKISH2, B. A. DAVIS2 1Neurochemical Research Unit, Department of Psychiatry, University of Alberta and 2Neuropsychiatric Research Unit, University of Saskatchewan, Canada Summary The functional aversive stimulus properties of several IP doses of (±)-amphetamine (1.25-10 mg.kg-1), 2-phenylethylamine (PEA, 2.5-10 mg.kg-1, following inhibition of monoamine oxidase with pargyline 50 mg.kg-1) and phenylethanolamine (6.25-50 mg.kg-1) were measured with the conditioned taste aversion (CTA) paradigm. A two-bottle choice procedure was used, water vs. 0.1 % saccharin with one conditioning trial and three retention trials. (±)-Amphetamine and phenylethanolamine induced a significant conditioned taste aversion but PEA did not. (±)-Amphetamine and PEA increased spontaneous locomotor activity but phenylethanolamine had no effects on this measure. Measurement of whole brain levels of these drugs revealed that the peak brain elevation of PEA occurred at approximately 10 min whereas the peak elevations of (±)-amphetamine and phenylethanolamine occurred at approximately 20 min. The present failure of PEA to elicit conditioned taste aversion learning is consistent with previous reports for this compound. The differential functional aversive stimulus effects of these three compounds are surprising since they exhibit similar discriminative stimulus properties and both (±)-amphetamine and PEA are self- administered by laboratory animals. The present data suggest that time to maximal brain concentrations following peripheral injection may be a determinant of the aversive stimulus properties of PEA derivatives. Key words 2-phenylethylamine • (±)-amphetamine • Phenylethanolamine • Conditioned taste aversion • Locomotor activity • Drug levels Introduction (Greenshaw et al.
    [Show full text]
  • The Role of Norepinephrine in the Pharmacology of 3,4
    !"#$%&'#$&($)&*#+,-#+"*,-#$,-$."#$/"0*102&'&34$&($ 56789#."4'#-#:,&;41#."01+"#.01,-#$<9=9>6$?#[email protected]@4AB$ $ C-0D3D*0':,@@#*.0.,&-$$ ! $ ED*$ F*'0-3D-3$:#*$GH*:#$#,-#@$=&I.&*@$:#*$/",'&@&+",#$ J&*3#'#3.$:#*$ /",'&@&+",@2"8)0.D*K,@@#-@2"0(.',2"#-$L0ID'.M.$ :#*$N-,J#*@,.M.$O0@#'$ $ $ J&-$ $ PQ:*,2$90*2$R4@#I$ 0D@$O#''1D-:6$OF$ $ O0@#'6$STU5$ $ $ V*,3,-0':&ID1#-.$3#@+#,2"#*.$0D($:#1$=&ID1#-.#-@#*J#*$:#*$N-,J#*@,.M.$O0@#'W$#:&2XD-,Y0@X2"$ $ =,#@#@$ G#*I$ ,@.$ D-.#*$ :#1$ Z#*.*03$ [P*#0.,J#$ P&11&-@$)01#-@-#--D-38\#,-#$I&11#*E,#''#$)D.ED-38\#,-#$ O#0*Y#,.D-3$ SX]$ ^2"K#,E_$ ',E#-E,#*.X$ =,#$ J&''@.M-:,3#$ `,E#-E$ I0--$ D-.#*$ 2*#0.,J#2&11&-@X&*3a',2#-2#@aY48-28 -:aSX]a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
    [Show full text]
  • Principles-Of-Autonomic-Medicine-V
    Principles of Autonomic Medicine v. 2.1 DISCLAIMERS This work was produced as an Official Duty Activity while the author was an employee of the United States Government. The text and original figures in this book are in the public domain and may be distributed or copied freely. Use of appropriate byline or credit is requested. For reproduction of copyrighted material, permission by the copyright holder is required. The views and opinions expressed here are those of the author and do not necessarily state or reflect those of the United States Government or any of its components. References in this book to specific commercial products, processes, services by trade name, trademark, manufacturer, or otherwise do not necessarily constitute or imply their endorsement, recommendation, or favoring by the United States Government or its employees. The appearance of external hyperlinks is provided with the intent of meeting the mission of the National Institute of Neurological Disorders and Stroke. Such appearance does not constitute an endorsement by the United States Government or any of its employees of the linked web sites or of the information, products or services contained at those sites. Neither the United States Government nor any of its employees, including the author, exercise any editorial control over the information that may be found on these external sites. Permission was obtained from the following for reproduction of pictures in this book. Other reproduced pictures were from -- 1 -- Principles of Autonomic Medicine v. 2.1 Wikipedia Commons or had no copyright. Tootsie Roll Industries, LLC (Tootsie Roll Pop, p. 26) Dr. Paul Greengard (portrait photo, p.
    [Show full text]
  • Demonstration and Distribution of Phenylethanolamine in Brain And
    Proc. Nat. Acad. Sci. USA Vol. 70, No. 3, pp. 769-772, March 1973 Demonstration and Distribution of Phenylethanolamine in Brain and Other Tissues (enzyme assay/intraneural synthesis and storage/phenylethylamine/phenylalanine/rat) JUAN M. SAAVEDRA AND JULIUS AXELROD Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20014 Contributed by Julius Axelrod, December 26, 1972 ABSTRACT A specific and sensitive assay for phenyl- of a mixture containing 10 ul of partially purified phenyl- ethanolamine in tissues is described. By this assay, phenyl- ethanolamine was detected in many peripheral tissues and ethanolamine N-methyltransferase, 5 Ml (0.54 nmol) of brains of rats. It is unequally distributed in rat brain, with [3H]methyl-S-adenosyl-l-methionine (specific activity, 4.54 the highest concentration present in hypothalamus and Ci/mmol) and 35 ul of 20 mM Tris * HCl buffer (pH 8.6). 1 ng midbrain. Concentrations of brain phenylethanolamine of phenylethanolamine was added to another aliquot as an were elevated after administration of phenylethylamine, internal standard. The incubation was stopped by addition of phenylalanine, p-chlorophenylalanine, and monoamine oxidase inhibitors and decreased after administration of 0.5 ml of 0.5 M borate buffer (pH 10) and the radioactive dopamine-fl-hydroxylase inhibitors. Denervation of sym- product was extracted with 6 ml of a mixture containing 95% pathetic nerves caused a moderate fall in phenylethanol- heptane and 5% isoamyl alcohol (v/v), by shaking for 15 sec. amine concentrations. These results indicate that phenyl- After the phases were separated by centrifugation, a 5-ml ethanolamine is synthesized intraneuronally from phenyl- alanine and phenylethylamine, but that only part of the aliquot of the organic phase was transferred to counting vials phenylethanolamine is stored in sympathetic nerves.
    [Show full text]